Press Releases - Bristol Myers Squibb
Receive updated news from preferred websites, which are sent directly to the user's news reader. This includes the headlines, summaries and links to the full article on the website. Learn how
Bristol Myers Squibb - Bristol Myers Squibb Adds Premier ...
Dec 26, 2023 · “Acquiring RayzeBio’s differentiated actinium-based radiopharmaceutical platform will establish Bristol Myers Squibb’s presence in one of the most promising and fastest-growing new modalities for the treatment of patients with solid tumors – delivering radioactive payloads to cancer cells in a targeted manner,” said Samit Hirawat, M.D ...
Bristol Myers Squibb - Bristol Myers Squibb to Present New …
Oct 28, 2024 · PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio evaluating COBENFY™ (xanomeline and trospium chloride) in schizophrenia in adults will be presented at Psych Congress 2024, taking place October 29 ...
Bristol Myers Squibb - Bristol Myers Squibb Completes Acquisition …
Mar 18, 2024 · Bristol Myers Squibb will provide an update to its financial outlook when it reports first quarter 2024 results on April 25, 2024. Advisors. Gordon Dyal & Co. and Citi are serving as financial advisors to Bristol Myers Squibb, and Covington & …
Bristol Myers Squibb - Bristol Myers Squibb Completes Acquisition …
Jan 23, 2024 · Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc. ® (“Mirati”). With the completion of the acquisition, Mirati shares have ceased trading on the NASDAQ Global Select Market and Mirati is now a wholly owned subsidiary of Bristol Myers Squibb.
Bristol Myers Squibb - Bristol Myers Squibb to Acquire Turning …
Jun 3, 2022 · NEW YORK & SAN DIEGO--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) today announced a definitive merger agreement under which Bristol Myers Squibb will acquire Turning Point Therapeutics for $76.00 per share. The transaction was unanimously …
Bristol Myers Squibb Announces Dividend Increase
Dec 11, 2024 · Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on February 3, 2025, to stockholders of record at the close of business on January 3, 2025.
Corporate news details - Bristol Myers Squibb
Oct 8, 2023 · Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring a ...
Bristol Myers Squibb - Bristol Myers Squibb Showcases the …
Nov 11, 2024 · PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its cardiovascular portfolio at the American Heart Association (AHA) Annual Scientific Sessions, taking place November 16-18, 2024, in Chicago, Illinois.
Bristol Myers Squibb - Bristol Myers Squibb Highlights Progress of …
Dec 9, 2024 · PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) announced results from 18 presentations reinforcing its leadership in cell therapy, with data demonstrating efficacy, durability and safety of currently available therapies in blood cancers and highlighting the potential of its pipeline for future indications including ...